



## PRESS RELEASE

### **Cipla wins USD 188.95 million of Global Fund ARV Tender**

**India, Mumbai, 13<sup>th</sup> February 2015:** Cipla, a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients - today announced that it has been awarded USD 188.95 million of Global Fund ARV Tender. Cipla has been selected as a 'Panel Supplier' for a Supplier Partnership Agreement. The contract is effective from the 1<sup>st</sup> of January 2015 and will run for a period of three years. The supplies will begin from Q4 FY 2015.

**Mr. Subhanu Saxena, MD & Global CEO, Cipla Limited** said: "We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund.

Cipla has a long-term association with Global Fund since 2002. Last year, Cipla has been one of the suppliers who has been awarded with a long-term contract for supplying anti-malarial drugs.

The anti-retrovirals drugs will be manufactured in Cipla's state-of-the-art manufacturing facilities in India, which has been approved by various international regulatory agencies.

#### **About Cipla Limited**

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Cipla's portfolio includes over 1500 products in various therapeutic categories with one quality standard globally. Cipla's turnover in 2013/14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

#### **About Global Fund**

The Global Fund is a 21<sup>st</sup>- century partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics. The Global Fund raises and invests nearly US\$4 billion a year to support programs run by local experts in more than 140 countries. Created in 2002,

the Global Fund operates as a partnership between governments, civil society, the private sector and people affected by the diseases. By challenging barriers and embracing innovative approaches, partners are better serving people affected by the diseases.

Programs supported by the Global Fund have put 7.3 million people on antiretroviral therapy for HIV, have tested and treated 12.3 million people for TB, and have distributed 450 million mosquito nets to protect families against malaria.

**Media Contact:**

Charlotte Chunawala  
Corporate Communications  
Mobile: +91 7506257377

E Mail id: [charlotte.chunawala@cipla.com](mailto:charlotte.chunawala@cipla.com);

Jaisingh Balakrishnan  
Corporate Communications  
Mobile: +91 9833836185

E Mail id: [jaisingh.krishnan@cipla.com](mailto:jaisingh.krishnan@cipla.com)